Table 1.

Phase-3 clinical trial with application of approved immune checkpoint inhibitors for the treatment of PDAC.

ICI Class	Drugs	Patients/Disease	Treatment	Clinical Trial	Status
PD-1 blocker, CTLA-4 blocker	Pembrolizumab and/or ipilimumab	Patients with hepatocarcinoma, lung cancer, melanoma, renal cancer, head and neck cancer, pancreatic cancer, ovarian cancer, colorectal cancer, cervical cancer, breast cancer	Vein, artery, or intra-tumour infusion of checkpoint inhibitor	NCT03755739	Recruiting

Clinicaltrials.gov was searched for the following combinations and selection criteria: Selection: “Phase 3”, combinations of “pancreatic cancer” or “PDAC” and “ipilimumab”, “tremelimumab”, “nivolumab”, “pembrolizumab”, “durvalumab”, “avelumab”, “atezolizumab”, or “cemiplimab”. Pancreatic cancer is highlighted to enable a more rapid recognition of the relevant disease concering this review.